神经调节在心力衰竭中发挥的作用,其中保留了喷射分数
Jumana Algheffari1, Abdel Rahman Salameh1, Lina Adil1
1School of Medicine, RCSI University of Medicine and Health Sciences, Dublin 2, 123 St. Stephen's Green, Dublin D02 YN77, Ireland.
Current problems in cardiology
|October 12, 2025
概括
神经调节疗法,如神经刺激 (VNS),在心力衰竭中具有保留射出分数 (HFpEF) 的治疗有希望. 虽然一些治疗方法可以改善症状和生活质量,但需要进一步的研究来确认长期的疗效和安全性.
科学领域:
- 心脏病学 心脏病学
- 神经学 神经学
- 医疗器械 医疗器械
背景情况:
- 保存喷射分数 (HFpEF) 的心力衰竭为改善长期结果提供了有限的治疗选择.
- 自主调节失调是HFpEF的一个关键因素,使神经调节疗法成为潜在的干预措施.
- 本综述重点关注四种神经调节疗法:脏消毒 (RDN),巴罗受体激活疗法 (BAT),神经刺激 (VNS) 和大神经 (GSN) 消去.
研究的目的:
- 批判性地评估神经调节装置在管理HFpEF中的作用.
- 评估这些疗法的机制,疗效和对患者结果的影响.
- 总结关于HFpEF的VNS,RDN,BAT和GSN临床试验的发现.
主要方法:
- 对HFpEF的神经调制疗法的临床试验和研究进行系统审查.
- 关注随机对照试验和可行性研究.
- 评估终点,包括功能状态,生活质量 (QoL),运动能力和不良事件.
主要成果:
- 神经刺激 (VNS) 在ANTHEM-HFpEF试验中证明了提高功能状态和自主性语调的有效性.
- 脏缺血 (RDN) 试验显示出混合的结果,一些症状和心脏功能得到改善,但持续存在限制.
- 巴罗受体激活疗法 (BAT) 和大神经 (GSN) 切除显示出减少交感活动和改善血液动力学参数的承诺,尽管需要进一步验证.
结论:
- 神经调节装置为管理HFpEF症状,QoL和功能状态提供了一个有希望的方法.
- 试验结果的变化凸显了持续研究的必要性.
- 进一步的研究是必不可少的,以充分确定这些神经调节疗法在HFpEF中的长期疗效和安全性.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
932
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
932
01:29Heart Failure II: Pathophysiology
722
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
722
01:30Heart Failure V: Medical Management
218
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
218
01:26Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
01:17Pathophysiology of Heart Failure
2.9K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.9K
01:22Heart Failure VI: Adjunct Therapies
255
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
255